AACR 2024 | Siltuximab and spartalizumab in advanced pancreatic adenocarcinoma

Olatunji Alese, MD, Emory Winship Cancer Institute, Atlanta, GA, presents the findings of a Phase Ib trial (NCT04191421) evaluating siltuximab and spartalizumab for advanced pancreatic ductal adenocarcinoma (PDAC). Although there was no objective response across the 31 patients treated, the findings provide a valuable opportunity to identify the potential resistance mechanisms that produced this result. Dr Alese highlights that this is crucial to further explore the complex role of the interleukin 6 blockade in PDAC. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.